BETH study: highly effective treatment option for patients with HER2 breast cancer

Bookmark and Share
Published: 12 Dec 2013
Views: 4083
Dr Dennis Slamon - University of California, Los Angeles

During a press conference at the SABCS 2013, Dr Dennis Slamon presents data from the recent BETH study.

Combining the chemotherapy drugs docetaxel and carboplatin with the HER2-targeted therapy trastuzumab was identified to be an ideal postsurgery treatment option for patients with HER2-positive breast cancer, regardless of tumour size and whether or not disease has spread to the lymph nodes, according to results from the study.